In the SURMOUNT program (SM), treatment with tirzepatide led to a significant and clinically meaningful reduction in body weight (BW) in overweight and obese subjects. In a post-hoc analysis, the effect of tirzepatide treatment on body weight in women was examined according to the stage of menopause.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Therapy of non-tumor-related pain
Do not prescribe opioids lightly for musculoskeletal pain
- Migraine
Fremanezumab for comorbid migraine and depression
- Case study
Moyamoya disease in a 23-year-old female patient
- Dapagliflozin for T2D and heart failure
Epicardial fat reduced in patients with type 2 diabetes and HF
- A hub of biological aging
Mitochondrial dysfunction and energy metabolism
- Health Literacy
Promoting health literacy: from the abstract to the concrete level
- Pharmacological therapy
Anxiety symptoms in eating disorders
- Case study